Best first-line therapy for patients with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status

Rolof G.P. Gijtenbeek*, Kim de Jong, Ben J.W. Venmans, Femke H.M. van Vollenhoven, Anneke Ten Brinke, Anthonie J. Van der Wekken, Wouter H. van Geffen

*Corresponding author for this work

    Research output: Contribution to journalArticleAcademicpeer-review

    4 Citations (Scopus)
    57 Downloads (Pure)

    Abstract

    This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To identify the best first-line therapy for advanced lung cancer in patients with performance status 2 without a targetable mutation or with an unknown mutation status.

    Original languageEnglish
    Article numberCD013382
    Number of pages14
    JournalCochrane Database of Systematic Reviews
    Volume2019
    Issue number8
    DOIs
    Publication statusPublished - 12-Aug-2019

    Fingerprint

    Dive into the research topics of 'Best first-line therapy for patients with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status'. Together they form a unique fingerprint.

    Cite this